BioNTech SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ugur Sahin
- Full Time Employees
- 7,807
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- An der Goldgrube 12 Mainz RP Germany 55131
- IPO Date
- Oct 10, 2019
- CIK
- 0001776985
- Website
- biontech.com
- Similar Companies
- Business
- BioNTech SE (BNTX) is a biotechnology company focused on developing and commercializing immunotherapies for cancer and infectious diseases. The company offers a broad portfolio of products and services, including mRNA-based therapeutics and vaccines such as Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer; individualized neoantigen-specific immunotherapies under the BioNTech's FixVac and iNeST platforms; antibody-drug conjugates; small molecule immunomodulators; and cell therapies targeting solid tumors and hematological malignancies; as well as oncology pipeline candidates like BNT327 (a PD-L1/VEGF bispecific antibody) and BNT116 (a next-generation FixVac for lung cancer). BioNTech operates primarily in the biopharmaceutical industry, serving global patient populations through clinical trials, regulatory approvals, and commercial distribution in over 30 countries across North America, Europe, Asia-Pacific, and emerging markets. Founded in 2008 and headquartered in Mainz, Germany, the company maintains subsidiaries worldwide, including in the United States, the United Kingdom, and China, with no parent company. Recent developments include the European Medicines Agency's approval in 2024 for BNT116 as the first mRNA-based lung cancer therapeutic; a multi-billion-dollar expansion of its manufacturing facilities in Rwanda and Australia announced in early 2025 to enhance global vaccine production capacity; deepened strategic alliances with Pfizer for next-generation COVID-19 vaccines and with Genentech for bispecific antibody development; and a $760 million funding round in late 2024 to advance its oncology pipeline amid robust Phase 3 trial progress.
Company News
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Reviewing MiMedx Group (NASDAQ:MDXG) and BioNTech (NASDAQ:BNTX)
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
BioNTech Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into BioNTech (BNTX)
BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 36,209 Shares
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 27,000 Shares
BioNTech (NASDAQ: BNTX) CEO sells all direct shares under trading plan
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
BioNTech (NASDAQ: BNTX) CEO sells 93,000 shares under preplanned deal
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
Moderna Climbs 3% Despite Citigroup's Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water
Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?
BioNTech to shutter sites in Germany, Singapore as no buyers emerge
BioNTech (NASDAQ:BNTX) Stock: Insider Ugur Sahin Sells 30,000 Shares